Brief: Novartis' Pluvicto™ Demonstrated Consistent Efficacy Across Key Patient Subgroups In Metastatic Hormone-Sensitive Prostate Cancer
31/05/2026 06:16
BRIEF-Novartis' Pluvicto™ Demonstrated Consistent Efficacy Across Key Patient Subgroups In Metastatic Hormone-Sensitive Prostate Cancer May 31 (Reuters) - Novartis AG NOVN.S:
PLUVICTO™ DEMONSTRATED CONSISTENT EFFICACY ACROSS KEY PATIENT SUBGROUPS IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
NOVARTIS AG - SECONDARY ENDPOINTS SUPPORT EARLY USE OF PLUVICTO IN PSMA+ METASTATIC PROSTATE CANCER
Source text: ID:nGNE33dLcG
Further company coverage: NOVN.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Novartis AG
See all newsBrief: Novartis Remind Data At Eaaci Show Rhapsido Potential As First Targeted Therapy For Chronic Inducible Urticaria (Cindu)
Swiss stocks - Factors to watch on June 12
Swiss pharma hub Basel frets over population cap threat
Novartis says rare muscle disease drug shows promise in early trial
Live Markets: Europe at half-time: countdown to the ECB's 'insurance hike'